Kelun-Biotech Advances First Dual-Payload ADC into Clinical Trials

Developed on the company’s proprietary OptiDC™ platform, SKB565 moves beyond traditional single-payload therapies by delivering both toxins and immunomodulators directly to diseased tissue. This combination approach aims to overcome common drug resistance patterns by attacking tumors through two complementary pathways. Preclinical data indicated the molecule possesses robust antitumor activity, clearing the path for the current regulatory milestone.

CEO Dr. Michael Ge described the candidate as a cornerstone of the firm’s “ADC + IO” strategy, which seeks to integrate synergistic functions into a single molecule. The company is currently managing over 30 innovative drug projects, with a heavy emphasis on solid tumors and metabolic diseases. As the industry shifts toward next-generation conjugates, Kelun-Biotech is positioning its integrated design strategy to address complex medical needs that conventional therapies often fail to resolve.